Introduction
============

Thyroid carcinoma is the most common endocrine-related malignancy worldwide. According to cell origin and pathological pattern, thyroid carcinomas are normally divided into four types: papillary, follicular, medullary, and anaplastic. The most common type of thyroid carcinoma is papillary thyroid carcinoma (PTC), accounting for 80% of all cases. Thyroid carcinoma is considered a curable disease, but an accurate diagnosis and appropriate risk evaluation are still necessary. Currently, the gold standard for thyroid nodule diagnosis is ultrasound-guided fine-needle aspiration biopsy, achieving correct final diagnoses in 70%--80% of cases; the remaining 20%--30% of cases are considered indeterminate for malignancy.[@b1-ott-8-2271] Operative strategy and prognosis are related to risk evaluation. High-risk tumors are often characterized by progressive features such as extrathyroid extension, lymph node metastasis, and distant metastasis.[@b2-ott-8-2271] In these cases, an extended surgery strategy should be performed.

MicroRNAs (miRNAs) are nonprotein-coding, endogenous small RNA molecules. They act as oncogenes as well as tumor suppressors by regulating the expression of target genes at the posttranscriptional level. There is evidence that miRNAs are involved in thyroid tumorigenesis and progression.[@b3-ott-8-2271]--[@b8-ott-8-2271] In the present study, we analyzed the expression profiles of miRNAs and genes retrieved from The Cancer Genome Atlas (TCGA; <http://cancergenome.nih.gov/>). A pivotal regulatory network of miRNAs associated with PTC was identified. The diagnostic values of miRNAs and genes in the regulatory network were examined, and the results indicated that diagnostic accuracy could be improved by the combination of miRNAs and targets. Furthermore, an association between miRNA and target expression levels and aggressive clinical features was detected.

Materials and methods
=====================

TCGA data access
----------------

The miRNA expression microarray data (Level 3), RNA expression microarray data (Level 3), and corresponding clinical data for thyroid cancer patients were obtained from TCGA. In total, 499 PTC samples and 58 control samples (paracancerous tissues) with complete miRNA, RNA, and clinical data were selected for inclusion in this study. The expression levels of 1,046 human miRNAs and 20,531 human genes in each sample were assessed using the Illumina's HiSeq system.

### TCGA background

TCGA was launched by the National Cancer Institute and the National Human Genome Research Institute in 2006. The program grew to include samples from 11,000 patients across 33 tumor types and currently represents the largest tumor collection, including key genomic and molecular characteristics. Findings for 13 cancer types have already been published, and as of late 2014, TCGA scientists have nearly completed the sequencing of protein-coding regions (exomes) for most tumor types and completed whole-genome sequencing of 1,000 tumor samples. The latter data characterize the complete genomic DNA sequence. Results from TCGA analyses have led to more than 2,700 articles in research journals to date.

### Data acquisition

From the TCGA homepage, <http://cancergenome.nih.gov>, the THCA (thyroid carcinoma) page was selected. All miRNASeq, RNASeqV2, and clinical data were chosen, and the Build Archive function was used. The miRNA and RNA expression data are classified as Level 3. In the miRNAseq section, files with the suffixes .miRNA, .quantification, and .txt were selected, and all files in the metadata and clinical sections were examined.

### Inclusion and exclusion criteria

The TCGA database consisted of 507 cases of thyroid carcinoma and 59 normal tissue samples. Excluding non-PTC samples and those lacking complete clinical information, 499 PTC samples and 58 normal tissue samples were included in the subsequent analyses.

Microarray analysis
-------------------

The raw data obtained from miRNA microarrays were normalized to the 75th percentile signal intensity as recommended by the vendor. After normalization, all negative signal values were replaced with 0.01 and the values for multiple replicate spots for each miRNA were summarized as median signals, which were used for statistical analyses.

To identify significantly upregulated and downregulated miRNAs, the pairwise Welch's *t*-test was applied to detect differences between c-Raf-transgenic and non-transgenic animal groups. The significance thresholds for the Welch's *t*-test were set to *P*\<0.05, fold-change \[FC\] \>2, and a mean signal of all samples \>50th percentile. Statistical and hierarchical clustering analyses were implemented in SAM (Significance Analysis of Microarrays) 3.01. In the tables and hierarchical clustering analyses, the FCs gene expression levels are given as signal logarithm ratios with base 2.

Prediction of miRNA target genes
--------------------------------

Target mRNAs were predicted using the web tools TargetScan (<http://www.targetscan.org/>) and PITA (<http://genie.weizmann.ac.il/pubs/mir07/index.html>). Both miRNA target prediction programs rely on sequence complementarities of the miRNA seed region (nucleotides 2--7) to the 3′-UTR sequences in candidate target genes. The results of the two analyses are summarized in a Venn diagram.

Statistical analysis
--------------------

Receiver operating characteristic curves for diagnostic value calculations were estimated using MedCalc 12.1.3.0 software (MedCalc Software, Mariakerke, Belgium). The area under the curve (AUC) represents the diagnostic accuracy for a specific criterion. The criterion is the threshold value for a laboratory test. Criteria listed in the tables are automated threshold values corresponding to the highest AUC values. Expression ratios of miRNAs and targets were calculated following the methods of Gordon et al.[@b9-ott-8-2271] Other statistical analyses were carried out using SPSS 17.0 (SPSS Inc., Chicago, IL, USA). Mann--Whitney *U*-tests were used to identify possible associations between miRNA and target expression levels and clinical features. A *P*-value less than 0.05 was considered statistically significant.

Results
=======

Expression profiles of miRNAs and genes
---------------------------------------

In total, 48 miRNAs and 2,731 genes were differentially expressed between the 499 PTC samples and 58 normal tissue samples. Of the 48 miRNAs, 18 were upregulated and 30 were downregulated (false discovery rate \[FDR\] \<0.01 and FC\>2). Of the 2,731 genes, 1,536 were upregulated and 1,195 were downregulated (FDR \<0.01 and FC\>2).

Regulatory network of miRNAs in PTC
-----------------------------------

Using starBase v2.0 (Jianhua Yang, Sun Yat-sen University, 2010--2013) to predict target genes, 30 miRNAs and 277 target genes were successfully predicted (data not shown). After Kyoto Encyclopedia of Genes and Genomes pathway mapping, 16 of 277 genes involved in cancer-related pathways were identified. Corresponding miRNAs were 17 of 30. The expression levels of 17 miRNAs and 16 target genes were visualized and are represented in [Figure 1](#f1-ott-8-2271){ref-type="fig"}. These miRNAs and target genes were pivotal in PTC because all of them were differentially expressed by at least twofold and played roles in cancer signaling pathways. The regulatory network is represented in [Figure 2](#f2-ott-8-2271){ref-type="fig"}.

Diagnostic value of pivotal miRNAs and genes
--------------------------------------------

To determine whether pivotal miRNAs and genes could be used to distinguish PTC from normal samples, receiver operating characteristic curves were applied to calculate diagnostic utility. AUC values, sensitivity, specificity, and the criterion for each miRNA and gene are listed in [Tables 1](#t1-ott-8-2271){ref-type="table"} and [2](#t2-ott-8-2271){ref-type="table"}. The miRNAs miR-222, miR-221, miR-146b, miR-34a, and miR-9-2 showed ideal diagnostic values with respect to AUC, sensitivity, and specificity, each of which was greater than 90%. The *CCND1* and *MET* genes showed ideal diagnostic values with respect to AUC, sensitivity, and specificity, each of which was greater than 90%.

To further improve the diagnostic power of miRNAs and genes, their combinations were examined. Inversely expressed miRNAs and target genes were considered novel markers. The expression ratios were estimated following the methods of Gordon et al.[@b9-ott-8-2271] Consistent with expectations, several miRNA and target combinations improved PTC diagnosis accuracy, as evidenced by the increased AUC value, sensitivity, and specificity. These combination markers are listed in [Table 3](#t3-ott-8-2271){ref-type="table"}. Among them, the miR-34a/*BCL2* combination substantially improved diagnostic accuracy (AUC of 0.989, sensitivity of 98.3%, and specificity of 98.4%) compared with miR-34a alone (AUC of 0.944, sensitivity of 0.983, and specificity of 0.984) and *BCL2* alone (AUC of 0.942, sensitivity of 84.5%, and specificity of 93.1%).

Association with high-risk clinical features
--------------------------------------------

In view of the essential roles of miRNAs and genes in the cancer signaling pathway and their use in effective tumor identification, we inferred that they may be related to progressive clinical signatures. We analyzed 499 PTCs and 58 normal tissue samples. Associations between lymph node metastasis ([Table 4](#t4-ott-8-2271){ref-type="table"}), miRNA and gene expression levels and extrathyroidal extension ([Table 5](#t5-ott-8-2271){ref-type="table"}), and high TNM classification stage ([Table 6](#t6-ott-8-2271){ref-type="table"}) were detected. Distant metastasis is commonly considered a high-risk clinical feature. Owing to the limited number of appropriate cases, distant metastasis was not explored in the present study.

The expression levels of miR-146b, miR-222, miR-221, miR-34a, miR-181a, miR-424, miR-138-1, miR-20b, and miR-152 were associated with PTC invasion or progression (*P*\<0.05). Among them, miR-146b and miR-222 were associated with all high-risk clinical features. miR-181b-1, miR-181a-2, miR-181b-2, miR-181d, miR-9-1, miR-9-2, miR-138-2, and miR-195 did not show a relationship with PTC invasion or progression.

The expression levels of *AXIN2*, *TRAF6*, *BCL2*, *RARB*, *HSP90B1*, *PDGFRA*, *RARA*, *RUNX1*, *ITGA2*, *MET*, and *CDKN1A* were associated with high-risk clinical features. Among them, *AXIN2*, *TRAF6*, *BCL2*, *HSP90B1*, *PDGFRA*, *RUNX1*, and *MET* were correlated with all high-risk clinical features. *FGF7*, *CCNE2*, *E2F1*, *CCND1*, and *COL4A1* showed no relationship with PTC invasion or progression.

Discussion
==========

The high incidence of thyroid disease in the population is problematic. As many as 50% of individuals have microscopic nodules, 3.5% have occult papillary carcinoma, and 15% have palpable goiters.[@b10-ott-8-2271] Currently, ultrasound-guided fine-needle aspiration biopsy is the most reliable method for detecting thyroid nodules. However, definitive diagnoses still cannot be made for 20%--30% of cases.[@b1-ott-8-2271] Therefore, additional methods that improve the sensitivity and specificity of diagnosis are highly desirable. Molecular markers such as BRAF, RAS, RET/PTC, PAX8/PPARγ, and galectin-3 may be considered for indeterminate cytology according to the American Thyroid Association guidelines.[@b11-ott-8-2271] Overcoming the challenges of accurate assessments of the risk for individual patients is important to establish appropriate treatment plans and optimize outcomes. An increasing number of mutations in thyroid tumors from low grade to high grade have been reported, indicating frequent recurrence and death.[@b12-ott-8-2271] In this context, molecular markers would facilitate tumor stage identification and risk stratification, assisting clinicians in determining appropriate treatment strategies, and in clinical monitoring.

miRNAs play important roles in multiple biological and metabolic processes, such as cell differentiation, proliferation, survival, and malignancy.[@b13-ott-8-2271],[@b14-ott-8-2271] Although numerous miRNAs involved in PTC have been identified, the global regulation of miRNAs in PTC remains unclear. In our study, we identified a pivotal regulatory network of miRNAs associated with PTC. All differentially expressed miRNAs and genes were screened using as many as 547 samples obtained from TCGA. Targeting relationships were reliable based on successful predictions by multiple common programs. All target genes played roles in cancer-related pathways. In all, 18 miRNAs and 20 target genes were core and vital in the regulation of PTC. Among the regulatory relationships, miR-146b targeting *TRAF6*, miR-222 targeting *AXIN2*, miR-181a/b targeting *BCL2*, miR-424 targeting *BCL2*, miR-34a targeting *PDGFRA* and *BCL2*, miR-138 targeting *RARA*, miR-20b targeting *CCND1* (also known as cyclin D1) and *RUNX1*, miR-195 targeting *CCND1*, and miR-152 targeting *MET* have been previously reported.[@b15-ott-8-2271]--[@b22-ott-8-2271] miR-181a/b targeting *HSP90B1*, miR-424 targeting *AXIN2/RARB/FGF7*, miR-181d targeting *BCL2* and *HSP90B1*, miR-144 targeting *RUNX1* and *CCNE2* (also known as cyclin E2), miR-363 targeting *CCNE2*, miR-195 targeting *ITGA2*, miR-20 targeting *LAMA3/CDKN1A* (also known as p21)/*E2F1*, and miR-152 targeting COL4A1 are newly identified.

Next, we sought to evaluate the diagnostic ability of the miRNAs and targets. The miRNAs miR-221, miR-222, miR-34a, and miR-9-2 displayed ideal diagnostic values based on the AUCs, sensitivities, and specificities greater than 90%. The *CCND1* and *MET* genes displayed ideal diagnostic values. All had potential use in PTC diagnosis for indefinite cases. Some studies have indicated that miRNA--target combinations can improve diagnostic accuracy;[@b9-ott-8-2271],[@b23-ott-8-2271] accordingly, we determined combinations based on miRNAs and targets with opposing expression patterns. Several combinations of miRNAs and targets showed higher diagnostic values compared with single factors. Particularly, the miR-34a/*BCL2* combination had an AUC value of 0.989, sensitivity of 98.3%, and specificity of 98.4% for certain criterion (expression ratio \>0.0731), which indicates that they are suitable tumor markers. Our results provide a novel combination method to improve diagnostic accuracy and can be validated in a wide range of cancer types.

Thyroid tumor markers are often related to high-risk clinical features and indicate poor prognosis.[@b12-ott-8-2271],[@b24-ott-8-2271] In the present study, we examined the associations between all pivotal miRNAs and genes and aggressive factors, including lymph node metastasis, extrathyroidal extension, and late-stage tumors. Nine of 17 miRNAs and eleven of 17 target genes were associated with at least one high-risk clinical feature. Clinical associations involving miR-221, miR-222, miR-146b, and miR-138-1 were supported by previous studies.[@b25-ott-8-2271]--[@b27-ott-8-2271] miR-34a, miR-424, miR-20b, and miR-152, which played roles in PTC progression and invasion, have not been previously reported. Differential expression of *CCND1*, *BCL2*, *MET*, *E2F1*, *RUNX1*, *ITGA2*, *RARA*, *PDGFRA*, and *CDKNA1* has been demonstrated for aggressive PTC in other studies.[@b28-ott-8-2271]--[@b36-ott-8-2271] Our study is the first to identify the association between *AXIN2*, *HSP90B1*, and *CDKNA1* and aggressive clinical features. The aberrant expression levels of miRNAs and genes identified in the present study can be used as diagnostic markers as well as treatment targets.

We identified novel miRNAs for PTC diagnosis and associations with aggression. Biofunction experiments and clinical validation of these miRNAs are our next goals to confirm their significance in PTC.

Conclusion
==========

In summary, we identified a set of pivotal thyroid cancer-related miRNAs and genes. Several novel targeting relationships were discovered. Many of these miRNAs and genes displayed potential value for the early diagnosis of PTC. Combinations of inversely expressed miRNAs and targets further improved the observed diagnostic accuracy. Based on their roles in the cancer pathway and clinical examinations, most of the miRNAs and genes in the present study were related to high-risk clinical features, indicating their potential use for risk stratification and prognosis for PTC patients. Our study indicates potential clinical applications of the miRNAs and genes for diagnosis, prognosis, and targeted treatment in thyroid malignant disease.

**Disclosure**

The authors report no conflicts of interest in this work.

![Differential expression of 17 miRNAs (**A**) and 16 target genes (**B**) in 499 PTC samples and 58 normal tissue samples retrieved from TCGA.\
**Note:** Red to green indicates decreasing expression levels of individual miRNAs or genes.\
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![Regulatory network of pivotal miRNAs in PTC.\
**Notes:** Red-marked miRNAs and genes were upregulated and blue-marked miRNAs and genes were downregulated. Key regulatory network nodes were identified, including many genes, such as *AXIN2*, *BCL2*, *CCND1*, *RUNX1*, *CCNE2*, and miRNAs such as miR-424, miR-181a/b/d, miR-20b, miR-195, miR-152, and miR-144. Regulatory networks formed by these key nodes are shown, including the internal relationships among thyroid cancer miRNAs and genes.\
**Abbreviations:** miRNAs, microRNAs; PTC, papillary thyroid carcinoma.](ott-8-2271Fig2){#f2-ott-8-2271}

###### 

Diagnostic value of differentially expressed miRNAs

  miRNAs       AUC     SEN    SPE    Criterion
  ------------ ------- ------ ------ --------------
  miR-221      0.961   91.4   96.6   \>503.6685
  miR-222      0.958   91.4   94.8   \>125.782
  miR-146b     0.95    84.5   96.6   \>2,194.6538
  miR-34a      0.944   91.4   94.8   \>178.0286
  miR-9-1      0.927   86.2   94.8   \<53.4904
  miR-144      0.924   94.8   81     \<502.158
  miR-9-2      0.924   91.4   91.4   \<74.6703
  miR-181b-2   0.919   86.2   91.4   \>13.2275
  miR-363      0.916   82.8   87.9   \<7.4676
  miR-195      0.913   77.6   96.6   \<38.8908
  miR-181a-2   0.897   87.9   89.7   \>2,924.7844
  miR-152      0.892   86.2   91.4   \<500.1376
  miR-138-1    0.883   81.0   94.8   \<45.2887
  miR-138-2    0.88    75.9   96.6   \<28.8837
  miR-20b      0.875   79.3   87.9   \<11.7008
  miR-181b-1   0.872   84.5   81.0   \>710.2916

**Abbreviations:** miRNAs, microRNAs; AUC, area under the curve; SEN, sensitivity (%); SPE, specificity (%).

###### 

Diagnostic value of differentially expressed genes

  Genes       AUC     SEN    SPE    Criterion
  ----------- ------- ------ ------ ---------------
  *CCND1*     0.963   91.4   93.1   \>5,178.2373
  *MET*       0.942   93.1   91.4   \>2,623.9624
  *BCL2*      0.942   84.5   93.1   \<2,647.5432
  *RARB*      0.94    82.8   94.8   \<226.8591
  *E2F1*      0.936   98.3   79.3   \>62.7434
  *RARA*      0.935   91.4   87.9   \>747.9881
  *TRAF6*     0.93    84.5   91.4   \<182.3617
  *RUNX1*     0.903   69     100    \>864.4198
  *FGF7*      0.894   81     93.1   \<115.4518
  *ITGA2*     0.89    82.8   96.6   \>405.4988
  *PDGFRA*    0.847   74.1   93.1   \<235.9651
  *HSP90B1*   0.841   58.6   100    \<30,834.7969
  *AXIN2*     0.836   70.7   91.4   \<400.454
  *CCNE2*     0.805   81     77.6   \>24.1202
  *COL4A1*    0.801   74.1   82.8   \>3,715.8176
  *CDKN1A*    0.793   86.2   63.8   \>2,494.7954

**Abbreviations:** AUC, area under the curve; SEN, sensitivity (%); SPE, specificity (%).

###### 

Diagnostic value of combinations of miRNAs and targets

  Combinations           AUC     SEN    SPE    Criterion
  ---------------------- ------- ------ ------ -----------
  miR-34a/*BCL2*         0.989   98.3   98.4   \>0.0731
  miR-181b-2/*BCL2*      0.97    94.8   94.8   \>0.0036
  miR-221/*AXIN2*        0.966   94.8   91.4   \>0.6077
  miR-222/*AXIN2*        0.963   93.1   94.1   \>0.2262
  miR-146b/*TRAF6*       0.962   91.4   93.1   \>6.8312
  miR-181a-2/*BCL2*      0.962   91.4   96.6   \>1.071
  miR-181b-2/*HSP90B1*   0.942   93     95     \>0.0003

**Abbreviations:** miRNAs, microRNAs; AUC, area under the curve; SEN, sensitivity (%) SPE, specificity (%).

###### 

Associations between miRNAs and genes with lymph node metastasis

  miRNA/gene   Lymph node metastasis (+)                                      Lymph node metastasis (−)   *P*-value
  ------------ -------------------------------------------------------------- --------------------------- -----------
  miR-146b     3.09 (2.78--3.16)[\*](#tfn4-ott-8-2271){ref-type="table-fn"}   2.97 (2.47--3.14)           0.024
  miR-222      2.75 (2.62--2.90)                                              2.65 (2.41--2.84)           0.000
  miR-221      3.31 (3.14--3.41)                                              3.23 (2.97--3.42)           0.004
  miR-181a-1   3.78 (3.68--3.91)                                              3.72 (3.59--3.88)           0.005
  miR-152      2.43 (2.30--2.53)                                              2.48 (2.31--2.68)           0.005
  *AXIN2*      2.39 (2.19--2.60)                                              2.47 (2.26--2.67)           0.044
  *TRAF6*      2.14 (2.05--2.22)                                              2.17 (2.08--2.25)           0.048
  *BCL2*       2.92 (2.73--3.06)                                              3.03 (2.87--3.06)           0.000
  *HSP90B1*    4.42 (4.31--4.57)                                              4.47 (4.36--4.67)           0.029
  *PDGFRA*     2.24 (1.93--2.58)                                              1.98 (1.54--2.39)           0.000
  *RARA*       3.09 (3.03--3.17)                                              3.04 (2.93--3.12)           0.000
  *RUNX1*      3.15 (2.99--3.31)                                              3.03 (2.68--3.21)           0.000
  *MET*        4.11 (3.93--4.22)                                              4.00 (3.57--4.17)           0.000

**Note:**

Original expressing data were log transformed.

**Abbreviation:** miRNAs, microRNAs.

###### 

Associations between miRNAs and genes with extra-thyroid extension

  miRNA/gene   Extrathyroidal extension (+)   Extrathyroidal extension (−)   *P*-value
  ------------ ------------------------------ ------------------------------ -----------
  miR-146b     4.49 (4.21--4.65)              4.30 (3.45--4.62)              0.000
  miR-222      2.72 (2.60--2.86)              2.63 (2.39--2.82)              0.000
  miR-221      3.31 (3.12--3.46)              3.21 (2.95--3.39)              0.000
  miR-34a      2.68 (2.50--2.84)              2.61 (2.45--2.79)              0.013
  miR-424      2.53 (2.29--2.76)              2.64 (2.38--2.84)              0.009
  miR-138-1    1.26 (1.10--1.54)              1.38 (1.19--1.60)              0.005
  miR-20b      0.72 (0.56--1.06)              0.98 (0.66--1.19)              0.000
  miR-152      2.45 (2.32--2.58)              2.49 (2.32--2.72)              0.014
  *AXIN2*      2.36 (2.18--2.55)              2.51 (2.31--2.69)              0.000
  *TRAF6*      2.14 (2.05--2.20)              2.18 (2.11--2.27)              0.000
  *BCL2*       2.89 (2.74--3.06)              3.06 (2.90--3.33)              0.000
  *RARB*       2.06 (1.91--2.21)              2.19 (1.97--2.43)              0.000
  *HSP90B1*    4.39 (4.30--4.52)              4.52 (4.38--4.65)              0.000
  *PDGFRA*     2.24 (1.90--2.58)              1.96 (1.47--2.39)              0.000
  *RARA*       3.09 (3.12--3.06)              3.04 (2.93--3.03)              0.000
  *RUNX1*      3.19 (2.95--3.33)              2.99 (2.58--3.17)              0.000
  *ITGA2*      3.28 (2.85--3.5)               2.92 (2.63--3.27)              0.000
  *MET*        4.13 (3.95--4.27)              3.96 (3.55--4.15)              0.000
  *CDKN1A*     3.80 (3.63--3.96)              3.74 (3.54--3.90)              0.019

**Abbreviation:** miRNAs, microRNAs.

###### 

Association between miRNAs and genes with later tumor stage

  miRNA/gene   III/IV stage        I/II stage          *P*-value
  ------------ ------------------- ------------------- -----------
  miR-146b     4.49 (4.08--4.68)   4.31 (3.58--4.61)   0.001
  miR-222      2.70 (2.52--2.85)   2.64 (2.38--2.83)   0.012
  miR-34a      2.69 (2.50--2.84)   2.61 (2.45--2.76)   0.004
  miR-424      2.53 (2.28--2.77)   2.63 (2.38--2.84)   0.014
  miR-138-1    1.27 (1.13--1.57)   1.38 (1.18--1.64)   0.045
  miR-20b      0.82 (0.56--1.9)    0.95 (0.67--1.16)   0.01
  *AXIN2*      2.38 (2.20--2.61)   2.49 (2.30--2.67)   0.005
  *TRAF6*      2.14 (2.05--2.20)   2.18 (2.11--2.26)   0.000
  *BCL2*       2.94 (2.75--3.11)   3.06 (2.89--3.30)   0.000
  *RARB*       2.09 (1.92--2.32)   2.18 (1.97--2.39)   0.004
  *HSP90B1*    4.40 (4.30--4.55)   4.52 (4.38--4.66)   0.000
  *PDGFRA*     2.22 (1.77--2.56)   1.96 (1.55--2.39)   0.002
  *RUNX1*      3.14 (2.88--2.28)   2.99 (2.67--3.20)   0.000
  *MET*        4.06 (3.86--4.21)   3.97 (3.54--4.17)   0.001

**Abbreviation:** miRNAs, microRNAs.
